Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2) is an accessory subunit of mitochondrial Complex I, the first and largest enzyme complex of the electron transport chain situated in the mitochondrial inner membrane. The protein consists of 99 amino acids and contributes to the hydrophobic fraction that helps anchor Complex I to the membrane and supports assembly and regulation. While NDUFA2 is not involved in the catalytic process of electron transfer, it is critical for proper complex formation and function. Mutations in the NDUFA2 gene cause mitochondrial Complex I deficiency and Leigh syndrome, a progressive neurodegenerative disorder characterized by early-onset neurological decline. There are no known drugs that selectively target NDUFA2, but pharmacological inhibition of Complex I indirectly affects its function in the electron transport chain.
Inhibition of electron transfer through mitochondrial Complex I; Disruption of proton pumping and mitochondrial membrane potential via Complex I blockade (generic for Complex I inhibitors like rotenone; not specific for NDUFA2 subunit)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2).